<?xml version='1.0' encoding='utf-8'?>

<rss version="2.0">
  <channel>
    <title>The Federal Register</title>
    <link>http://thefederalregister.com/b.p/department/DEPARTMENT_OF_HEALTH_AND_HUMAN_SERVICES/2006-11-22/</link>
    <description>Daily Publications of Meetings and Rules Changes for the Federal Government</description>
    <pubDate>Fri, Dec 5 2008 11:00:00 GMT</pubDate>
    <lastBuildDate>Fri, Dec 5 2008 11:00:00 GMT</lastBuildDate>
    <webMaster>info@thefederalregister.com</webMaster>
    <item>
  <title><![CDATA[  Notification and Obligation of the Federal Employee  Antidiscrimination and Retaliation Act of 2002]]></title>
  <link>http://thefederalregister.com/d.p/2006-11-22-06-9361</link>
  <description><![CDATA[ This notice announces the notification and obligation of the 
Federal Employee Antidiscrimination and Retaliation Act of 2002 (No 
Fear Act). This notice is in compliance with the notification 
provisions set forth in Title II of the Notification and Federal 
Employee Antidiscrimination and Retaliation Act of 2002. The No FEAR 
Act requires that all Federal agencies publish an initial notice in the 
Federal Register informing Federal employees, former Federal employees, 
and applicants of the rights and protections available to them under 
Federal antidiscrimination and whistleblower protection laws.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2006-11-22-06-9361</guid>
  <pubDate>Wed, Nov 22 2006 11:00:00 GMT</pubDate>
</item>
<item>
  <title><![CDATA[  Guidance for Industry and Food and Drug Administration Staff;  Saline, Silicone Gel, and Alternative Breast Implants;]]></title>
  <link>http://thefederalregister.com/d.p/2006-11-22-06-9325</link>
  <description><![CDATA[ The Food and Drug Administration (FDA) is announcing the 
availability of the guidance entitled ``Saline, Silicone Gel, and 
Alternative Breast Implants.'' This version of the guidance document 
updates preclinical, clinical, and labeling recommendations described 
in ``Guidance for Saline, Silicone Gel, and Alternative Breast 
Implants,'' dated January 13, 2004. The update is based on the latest 
scientific and medical information on breast implants, and clarifies 
the type and amount of scientific data that should be submitted to 
allow FDA to evaluate whether these devices are safe and effective.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2006-11-22-06-9325</guid>
  <pubDate>Wed, Nov 22 2006 11:00:00 GMT</pubDate>
</item>
<item>
  <title><![CDATA[  Draft Guidance for Industry on Sinusitis: Designing Clinical  Development Programs of Nonantimicrobial Drugs for]]></title>
  <link>http://thefederalregister.com/d.p/2006-11-22-E6-19689</link>
  <description><![CDATA[ The Food and Drug Administration (FDA) is announcing the 
availability of a draft guidance for industry entitled ``Sinusitis: 
Designing Clinical Development Programs of Nonantimicrobial Drugs for 
Treatment.'' Sinusitis is a common disease affecting an estimated 16 
percent of the adult U.S. population annually. At present, other than 
antimicrobials, the treatment options for sinusitis are limited. This 
guidance is intended to assist the pharmaceutical industry in designing 
clinical development programs for nonantimicrobial drug products for 
the treatment of sinusitis.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2006-11-22-E6-19689</guid>
  <pubDate>Wed, Nov 22 2006 11:00:00 GMT</pubDate>
</item>
<item>
  <title><![CDATA[  Children's Hospitals Graduate Medical Education Payment Program  (CHGME PP)]]></title>
  <link>http://thefederalregister.com/d.p/2006-11-22-E6-19688</link>
  <description><![CDATA[ This document announces a scheduled CHGME PP conference call 
for Federal fiscal year (FY) 2007. The purpose of this conference call 
is to discuss new annual reporting requirements as required under 
Public Law (Pub. L.) 109307 for children's hospitals participating in 
the CHGME PP.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2006-11-22-E6-19688</guid>
  <pubDate>Wed, Nov 22 2006 11:00:00 GMT</pubDate>
</item>
</channel>
</rss>

